Basal cell carcinomas: attack of the hedgehog.
Ervin H Epstein
https://pubmed.ncbi.nlm.nih.gov/18813320/Actively Recruiting
Led by Nathalie Zeitouni · Updated on 2026-01-29
20
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the combination of Blue-Light Photodynamic Therapy PDT and Sonidegib as a possible treatment for people with multiple basal cell carcinoma BCC lesions. This study focuses on participants who have at least three nodular BCC lesions and aims to assess the safety and effectiveness of this approach compared to standard treatments like freezing or surgery, which can cause scarring. Sonidegib is an FDA-approved oral drug for BCC, and PDT uses a special blue light with a topical drug to target cancer cells without causing scarring. Participants will take Sonidegib 200 mg orally every day on an empty stomach for three months. They will also receive three sessions of PDT, where the drug aminolevulinic acid ALA is applied to the skin lesions and then activated by blue light using a BLU-U device. These PDT sessions occur on Day 7, Day 45, and Day 75. The light treatment may cause warmth or stinging sensations but is not expected to cause scarring. During the study, participants will undergo regular evaluations including monitoring for side effects possibly related to the study drug and assessments of disease progression. The primary outcomes will be reviewed from enrollment through day 180. Participants will also have blood tests and clinical exams to check liver, kidney, and blood function. The total study duration is about six months, with treatment and follow-up visits scheduled to closely monitor safety and response to the combination therapy.
CONDITIONS
Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas
S
Sonja Stutzman Clinical Trial Manager, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Nathalie Zeitouni
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Blue-Light Photodynamic Therapy with ALA and Sonidegib (trial intervention) | Established Nonsurgical Treatments for Multiple BCC (external context) |
|---|---|---|
| What is it? | A novel approach combining topical aminolevulinic acid and blue-light photodynamic therapy, followed by oral sonidegib, for patients with multiple basal cell carcinoma lesions who are not surgical candidates. | Current nonsurgical options for multiple BCC include topical treatments like imiquimod or fluorouracil, systemic hedgehog pathway inhibitors such as sonidegib or vismodegib, and photodynamic therapy alone, based on clinical guidelines and practice reviews. |
| Primary use | Investigated for reducing tumor burden and controlling multiple nodular BCC lesions in patients who may not tolerate surgery. | Used to manage and shrink BCC tumors when surgery is not possible or suitable, especially for patients with multiple lesions. |
| How is it given or performed? | ALA is applied to cleaned and debrided lesions, incubated under occlusion, followed by blue-light illumination using the BLU-U device. Sonidegib is taken orally as prescribed. | Topical treatments are applied to affected skin areas according to protocol; systemic hedgehog pathway inhibitors are administered orally; standalone PDT involves topical photosensitizer incubation followed by light exposure. |
| Evidence status | Ongoing early-phase trial; no published outcome data as of yet. Previous reports support blue-light PDT and sonidegib each as effective for certain BCC populations, but results for combination therapy are not established. | Extensively studied, with published data showing response rates for topical treatments, hedgehog inhibitors, and PDT. Effectiveness varies with disease burden, tumour subtype, and eligibility; long-term outcomes and tolerability are well described in review literature. |
| Important limitations | As an early-phase single-arm trial, this protocol lacks a randomized comparator. Patient selection excludes those with aggressive histological subtypes or large target lesions requiring Mohs surgery. Safety and efficacy in broader BCC populations, or for the combined approach, are not yet established. | Current-care therapies may be less effective for nodular, larger, or aggressive BCC subtypes. Topical agents and PDT are limited to superficial/low-burden lesions, while hedgehog inhibitors carry tolerability and side-effect concerns. Published reviews caution limited durability and risk of recurrence for nonsurgical approaches. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 months
Participants receive Sonidegib 200 mg by mouth daily for 3 months and undergo three photodynamic therapy sessions with topical application of ALA on Day 7, Day 45, and Day 75.
5 in-person visits including 3 PDT sessions on Day 7, Day 45, and Day 75
Duration - Up to 3 months after treatment ends
Participants are monitored for safety and efficacy outcomes up to Day 180 after enrollment.
Visits as scheduled up to Day 180
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Ervin H Epstein
https://pubmed.ncbi.nlm.nih.gov/18813320/Julien Lanoue, Gary Goldenberg
https://pubmed.ncbi.nlm.nih.gov/27386043/Edward V Maytin, Urvashi Kaw, Muneeb Ilyas...
https://pubmed.ncbi.nlm.nih.gov/29471147/Aleksandr Itkin, Barbara A Gilchrest
https://pubmed.ncbi.nlm.nih.gov/15209801/Nathalie Zeitouni
Lead Sponsor